John P Overington
Overview
Explore the profile of John P Overington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
9030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Repurposing Vandetanib plus Everolimus for the Treatment of -Mutant Diffuse Intrinsic Pontine Glioma
Carvalho D, Richardson P, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, et al.
Cancer Discov
. 2021 Sep;
12(2):416-431.
PMID: 34551970
Somatic mutations in are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence-based...
2.
Schmidt A, Carter J, Pearce L, Wilkins J, Overington J, Hingorani A, et al.
Cochrane Database Syst Rev
. 2020 Oct;
10:CD011748.
PMID: 33078867
Background: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may...
3.
Levin J, Oprea T, Davidovich S, Clozel T, Overington J, Vanhaelen Q, et al.
Nat Biotechnol
. 2020 Sep;
38(10):1127-1131.
PMID: 32929264
No abstract available.
4.
Hingorani A, Kuan V, Finan C, Kruger F, Gaulton A, Chopade S, et al.
Sci Rep
. 2019 Dec;
9(1):18911.
PMID: 31827124
Lack of efficacy in the intended disease indication is the major cause of clinical phase drug development failure. Explanations could include the poor external validity of pre-clinical (cell, tissue, and...
5.
De Rycker M, Horn D, Aldridge B, Amewu R, Barry 3rd C, Buckner F, et al.
ACS Infect Dis
. 2019 Dec;
6(1):3-13.
PMID: 31808676
In May 2019, the Wellcome Centre for Anti-Infectives Research (CAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering...
6.
Oprea T, Bologa C, Brunak S, Campbell A, Gan G, Gaulton A, et al.
Nat Rev Drug Discov
. 2018 Mar;
17(5):377.
PMID: 29567993
This corrects the article DOI: 10.1038/nrd.2018.14.
7.
Oprea T, Bologa C, Brunak S, Campbell A, Gan G, Gaulton A, et al.
Nat Rev Drug Discov
. 2018 Feb;
17(5):317-332.
PMID: 29472638
A large proportion of biomedical research and the development of therapeutics is focused on a small fraction of the human genome. In a strategic effort to map the knowledge gaps...
8.
Tang J, Tanoli Z, Ravikumar B, Alam Z, Rebane A, Vaha-Koskela M, et al.
Cell Chem Biol
. 2017 Dec;
25(2):224-229.e2.
PMID: 29276046
Knowledge of the full target space of bioactive substances, approved and investigational drugs as well as chemical probes, provides important insights into therapeutic potential and possible adverse effects. The existing...
9.
Tresadern G, Trabanco A, Perez-Benito L, Overington J, van Vlijmen H, van Westen G
J Chem Inf Model
. 2017 Nov;
57(12):2976-2985.
PMID: 29172488
Proteochemometric modeling (PCM) is a computational approach that can be considered an extension of quantitative structure-activity relationship (QSAR) modeling, where a single model incorporates information for a family of targets...
10.
Mugumbate G, Mendes V, Blaszczyk M, Sabbah M, Papadatos G, Lelievre J, et al.
Front Pharmacol
. 2017 Oct;
8:681.
PMID: 29018348
Mycobacterium phenotypic hits are a good reservoir for new chemotypes for the treatment of tuberculosis. However, the absence of defined molecular targets and modes of action could lead to failure...